MPR Weekly Dose MPR 122 — Nasal Spray for Allergic Rhinitis; Qsymia Approval Expanded; Monkeypox Vaccine; Antibodies Shelf Life Extended; FDA Ban JUUL Products

New nasal spray for allergic rhinitis; weight management drug indication is expanded to include teens; monkeypox vaccine access; COVID-19 antibody shelf-life extension; JUUL banned in the US.

Episode metadata supplied by the publisher feed · Published Jul 1, 2022

Embed this episode

Attribution link and audio player

Ready to play

MPR Weekly Dose MPR 122 — Nasal Spray for Allergic Rhinitis; Qsymia Approval Expanded; Monkeypox Vaccine; Antibodies Shelf Life Extended; FDA Ban JUUL Products

0:00 12:29

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of MPR Weekly Dose?

This episode is 12 minutes long.

When was this MPR Weekly Dose episode published?

This episode was published on July 1, 2022.

Can I download this MPR Weekly Dose episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!